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Sequence Variants of the Brain-Derived Neurotrophic Factor (BDNF) Gene
Are Strongly Associated with Obsessive-Compulsive Disorder
Diana Hall,1 Alefiya Dhilla,2 Anna Charalambous,1 Joseph A. Gogos,2 and Maria Karayiorgou1
1The Rockefeller University, Human Neurogenetics Laboratory, and 2Columbia University, College of Physicians & Surgeons, Department of
Physiology and Cellular Biophysics and Center for Neurobiology & Behavior, New York
We evaluated a possible association between the brain-derived neurotrophic factor (BDNF) gene and susceptibility
to obsessive-compulsive disorder (OCD) by genotyping a number of single-nucleotide polymorphisms (SNPs) and
one microsatellite marker from the extended BDNF locus in 164 triads with OCD. Extensive background linkage
disequilibrium was observed at this locus. Single-locus transmission-distortion tests revealed significant evidence of
association with the disease for all the BDNF gene markers tested, including a Val66Met variation affecting the
sequence of the proBDNF protein. Analysis of multi-SNP haplotypes provided similar results. Haplotype trans-
mission comparisons in this and previous studies point to a functionally distinct BDNF haplotype uniquely marked
by the rare Met66 allele, which is undertransmitted and likely confers a protective effect in OCD and other psychiatric
disorders.
Brain-derived neurotrophic factor (BDNF) is a member
of the neurotrophin superfamily, which includes growth
factors that promote cell survival, differentiation, and
cell death. They are synthesized as proforms that can be
cleaved intracellularly to release mature, secreted ligands.
Mature neurotrophins selectively bind to members of the
Trk family of receptor tyrosine kinases that promote
Trk-mediated differentiation or survival (Friedman and
Greene 1999). It is interesting that proneurotrophins are
not inactive precursors, since they can be secreted and
cleaved extracellularly and serve as high-affinity ligands
for p75 NTR, which promotes apoptosis in neurons and
oligodendrocytes (Lee et al. 2001). Neurochemical and
behavioral analysis of heterozygous Bdnf/ mice re-
vealed that a partial impairment in BDNF expression
causes physiological disturbances in central serotonergic
(5-HT) neurons in early adulthood and eventually leads
to a structural deterioration of these neurons in ad-
vanced age (Lyons et al. 1999). These functional deficits
were associated with impaired impulse control, mani-
fested as exaggerated aggressiveness and excessive ap-
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petite/food intake. The heightened aggressiveness in
Bdnf/ mice was ameliorated by chronic treatment with
the selective serotonin-reuptake inhibitor (SSRI) fluox-
etine, a strategy that augments 5-HT neurotransmission
in the brain.
Patients afflicted with obsessive-compulsive disorder
(OCD [MIM 164230]) experience intrusive, disturbing,
repetitive thoughts (obsessions) and the uncontrollable
urge to repeatedly enact stereotypic behaviors or rituals
(compulsions), thereby reducing the psychic anxiety pro-
duced by the obsessional process (American Psychiatric
Association 1994). The lifetime prevalence rate of OCD
is ∼1%–2% (Flament et al. 1988). Several lines of evi-
dence indicate that it is associated with deficient 5-HT
neurotransmission (Insel et al. 1985), and patients with
OCD respond relatively well to chronic treatment with
SSRIs (Goodman et al. 1997). We therefore tested the
BDNF locus on chromosome 11p13 for association to
OCD in 164 proband-parent trios. We initially genotyped
four SNPs and one microsatellite marker, spread over a
distance of 56 kb at the BDNF gene (fig. 1a). The choice
of markers for genotyping was governed by the follow-
ing considerations: First, the BDNF mRNA that contains
exon 3 was shown to be the major Ca2/activity-induci-
ble transcript in cortical neurons (Tao et al. 1998; West
et al. 2002), via the CREB family transcription factors,
which control adaptive neuronal responses. We reasoned
that variants at this peculiar regulatory region may con-
tribute to the OCD phenotype and therefore tested two
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SNPs (SNP 1 [rs988748] and SNP 2 [rs2049046]) lo-
cated in the region immediately upstream of exon 3 (fig.
1a). Second, we tested one SNP (SNP 3 [rs6265]) that
determines a valinermethionine substitution at amino
acid position 66 of the preprotein (fig. 1b), which is
highly conserved across species. Finally, in the course of
our work, Sklar et al. (2002) and Neves-Pereira et al.
(2002) reported independently an association between
various SNPs and one microsatellite from the BDNF
locus and bipolar disorder. To facilitate cross referencing
with these studies, we chose to genotype one SNP from
the Sklar et al. study (a20, coded as “SNP 4” in our
study, located in the 3′-UTR region [fig. 1a]), as well as
the microsatellite marker from the Neves-Pereira et al.
study (referred to as “BDNF(CA),” located in intron 5,
immediately upstream of coding exon 6 [fig. 1a]). Each
SNP was genotyped by use of an allele-specific restric-
tion-site assay. Primers for all SNPs were designed from
the sequence available at the UCSC site. Samples were
digested for 3 h with the enzymes BsmAI, BsaI, NlaIII,
and Eco0109I for SNPs 1, 2, 3, and 4, respectively.
The proband sample consisted of 164 individuals (78
males, 86 females) who met lifetime criteria for OCD,
according to the Diagnostic and Statistical Manual, 4th
edition (DSM-IV) (American Psychiatric Association
1994). Of the sample, ∼85% were recruited through
advocate newspapers, with the remaining 15% referred
by local treating clinicians. The study was approved by
the Rockefeller University institutional review board, and
all subjects provided written informed consent prior to
their participation in the study. Subjects or the parents
of minors were interviewed by specially trained doctoral-
candidate clinicians, who used the Diagnostic Interview
for Genetic Studies (DIGS) (Nurnberger et al. 1994). To
ensure the accurate detection of DSM-IV OCD, detailed
screen, symptom, and impairment questions ascertaining
all DSM-IV OCD criteria were added, as described in
detail elsewhere (Sobin et al. 1999). Patients with OCD
onset following the onset of another psychiatric disorder
(e.g., major depressive disorder [MDD]) were not ex-
cluded from this study. However, patients with multiple
psychiatric disorders whose DSM-IV OCD was never the
focus of treatment or never the cause of primary distress
were excluded from these analyses. Analyses of demo-
graphic and clinical characteristics suggested that the sam-
ple is quite heterogeneous and represents a wide range of
onset ages, severity levels, and clinical phenomenology
(Sobin et al. 1999). To account for the clinical hetero-
geneity of our sample, as well as for the age-dependent
effects of BDNF-deficiency observed in animal models,
our analysis included two age-at-onset liability classes:
patients with childhood-onset (CO) (!18 years) OCD and
patients with adult-onset (AO) (18 years) OCD. The
CO sample included 38 children with DSM-IV OCD
(mean interview age years; 82% 110 years;12.4 3.3
50% male) and 82 adults, age 19 years, who reported
OCD onset prior to age 18 years (mean interview age
years; 46% male). The AO sample included31.2 8.8
44 adults, age 19 years, who reported OCD onset at
age 18 years (mean interview age years;25.3 8.0
48% male). A comparison of the phenotypic character-
istics of the CO and AO subsets of patients found that
CO OCD was characterized by a relatively aggressive
course and a greater number of obsessions and compul-
sions, unrelated to the amount of time in illness, which
indicates that CO OCD is a more severe form of illness
(Sobin et al. 2000). The two groups do not have any
statistically significant differences in the frequency of com-
orbid disorders, including other anxiety disorders, bipolar
disorder, phobias, eating disorders, tics, or Tourette syn-
drome (although a trend for an increased prevalence of
eating disorders, tics, and Tourette syndrome in the CO
sample was observed) (data not shown).
The single-locus test for excess of transmission of al-
leles from heterozygous parents to affected offspring
(transmission/disequilibrium test [TDT] [Spielman et al.
1993]) revealed significant evidence of association to the
disease for all the markers tested (table 1). The strongest
evidence was obtained at SNPs 1, 3, and 4 for the total
sample ( ). Two-locus tests performed by use ofPp .0005
a likelihood-based method, from the program TRANS-
MIT v2.5.2 (Clayton 1999), provided similar results. It
is interesting that a highly significant association was
observed only when the CO subset or the total sample
was considered. By contrast, none of the loci analyzed
were significant at the level in the subset of fami-Pp .05
lies with AO. Although not statistically significant, the
transmissions of the alleles in the families with AO re-
vealed identical distortions to those observed in the sam-
ple with CO, therefore contributing to the overall highly
significant association in the entire sample. Our inability
to observe statistical significance could be due to the over-
all effect of the allele being modest in the subset with AO
or to the relatively small sample size of the subset with
AO. Larger samples may be required to obtain conclu-
sive results.
We also observed significant evidence for association
at the multiallelic marker BDNF(CA), using the program
ETDT v1.9 (Sham and Curtis 1995) (table 2). Three al-
leles showed significant transmission distortions; allele
2 and allele 5 appeared to be undertransmitted, whereas
allele 3 is overtransmitted; the allelewise global test cal-
culated over 6 df showed in the entire sample,Pp .009
with the subset with CO demonstrating the most striking
transmission distortion. Comparison with the Neves-Pe-
reira et al. (2002) study shows that the same allele is
overtransmitted in both studies.
To investigate further the presence of a specific allelic
combination associated with an increased risk of OCD,
we performed multi-SNP haplotype analysis, using
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Table 1
Single-Locus and Two-Locus Analysis for Diallelic Markers
SNP LOCATIONa Nb AAc
CO
( )np 120
AO
( )np 44
ENTIRE SAMPLE
( )np 164
Single Locus Two Loci Single Locus Two Loci
Single Locus
(95% CI)d Two Loci
1 44645 C:G nc .003e .08f .0005; .50 (.34–.74)
.017g .25g .004g
2 43675 A:T nc .02h .30i .012; .66 (.48–.90)
.002j .32j .001j
3 196 G:A Val/Met .001k .16l .0005; .44 (.26–.74)
.009m .30m .004m
4 11757 C:G nc .0025n .08o .0005; .51 (.34–.75)
NOTE.—Significant associations are shown in italics.
a SNP location calculated from the ATG for BDNF.
b N p nucleotide change.
c AA p amino acid substitution; nc p noncoding region.
d Approximate relative risk; data based on distribution of alleles on transmitted and nontransmitted chromosomes.
e C:G transmission ratios 51:25.
f C:G transmission ratios 21:11.
g Two-locus analysis (SNP 1 and SNP 2).
h T:A transmission ratios 76:50.
i T:A transmission ratios 26:19.
j Two-locus analysis (SNP 2 and SNP 3).
k G:A transmission ratios 42:17.
l G:A transmission ratios 16:9.
m Two-locus analysis (SNP 3 and SNP 4).
n C:G transmission ratios 50:24.
o C:G transmission ratios 18:9.
Table 2
Single-Locus Analysis for BDNF(CA)
SAMPLE AND
TRANSMISSIONSa
ALLELES
Pb1 2 3 4 5 6 7
CO: .008
T 1 4 44c 3 17d 0 …
nT 3 11 16c 4 34d 1 …
AO: .539
T 0 2 14 2 8 … …
nT 1 5 10 1 9 … …
Entire Sample: .009
T 1 6e 58f 5 25g 0 1
nT 4 16e 27f 5 43g 1 0
NOTE.—Significant associations are shown in italics.
a Tp transmitted; nT p nontransmitted.
b Allelewise global P value.
c P p .0003.
d .Pp .0173
e .Pp .0331
f P p .0008.
g .Pp .0291
TRANSMIT v2.5.2 (Clayton 1999) (table 3). To avoid
very small haplotype frequencies, our analysis considered
all the families and included only the diallelic polymor-
phisms. The BDNF gene shows limited haplotype diver-
sity over a region of 56 kb, which is likely adequately
captured by the SNPs genotyped here. Specifically, in our
data set, we observed 10 haplotypes, of which only 4
were present with probabilities 13% and accounted for
the vast majority of the haplotype diversity (98%). Of
these, haplotype 2 is significantly overtransmitted to the
probands with OCD, and haplotype 4 is undertrans-
mitted. The allelic composition of the haplotypes reflects
the single-locus results with a preferentially transmitted
CTGC haplotype ( ) and an undertransmittedPp .007
GAAG haplotype ( ). The global P value is .003Pp .002
for the four most common haplotypes and .022 for all
possible haplotypes (table 3). It is notable that all four
psychiatric disease data sets tested to date for association
with BDNF (the OCD data set tested by the current
study, two bipolar data sets tested by Sklar et al. [2002],
and one bipolar data set tested by Neves-Pereira et al.
[2002]) share undertransmission of haplotype 4, which
is uniquely marked by the rare A allele of SNP 3 (which
results in methionine at codon 66 and was typed in all
studies), as well as by allele G of SNP 4 (typed in the
current study and the study of Sklar et al. [2002]). On
the other hand, haplotype overtransmission is less con-
sistent among the various data sets. This may reflect the
presence of more than one functionally equivalent
“risk”—or even “neutral”—haplotypes versus one func-
tionally distinct “protective” haplotype that is marked
by the rare alleles of SNPs 3 and 4. In that respect, it is
of interest that age-at-onset comparisons among the 164
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Table 3
Haplotype Transmission Analysis
Haplotype SNP 1 SNP 2 SNP 3 SNP 4
Estimated
Probability Oa Eb Var(O-E)c x2 (P)
1 C A G C .308 101.38 99.94 38.018 .054 (.816)d
2 C T G C .467 169.09 151.41 42.525 7.346 (.007)d
3 G A G G .042 11.71 13.73 6.500 .628 (.428)d
4 G A A G .162 38.78 52.35 19.732 9.332 (.002)d
For 4 haplotypes more frequent than .03 (df 4) … … … … … … … … 15.814 (.003)
Total haplotypes (df 9) … … … … … … … … 19.463 (.022)
a O p observed transmissions of haplotype to affected offspring.
b E p expected transmission under Mendelian inheritance.
c Var(O-E) p variance of (O-E).
d P value calculated for 1 df.
Table 4
Background LD in the BDNF Gene and Neighboring Regions
Distance
(kb) Frequencya Marker rs3763965 rs2352802 rs972096 rs1387145 SNP 1 SNP 2 SNP 3 SNP 4 rs1464896 rs2140887
19 47 rs3763965 .24 .33 .93 .27 .45 .20 .24 .02 .00
4.5 22 rs2352802 1.00 .08 .25 .04 .07 .05 .07 .00 .00
48 23 rs972096 .85 .87 .37 .58 .24 .49 .66 .02 .00
104 47 rs1387145 1.00 1.00 1.00 .27 .49 .19 .26 .02 .00
1 28 SNP 1 .80 .72 .79 .89 .26 .65 .87 .04 .00
44 42 SNP 2 .82 .66 .89 .82 .97 .16 .23 .01 .01
12 22 SNP 3 .80 .83 .86 .88 .94 .89 .77 .03 .00
125 27 SNP 4 .79 .86 .86 .88 .95 .91 1.00 .04 .00
63 27 rs1464896 .23 .21 .14 .21 .21 .17 .20 .21 .13
… 44 rs2140887 .01 .12 .06 .03 .10 .01 .06 .08 .52
NOTE.—For each pair of markers, the standardized D′ is shown below the diagonal, and the r2 is shown above the diagonal. D′ values 10.6
are shown in italics.
a Percent of minimum allele frequency calculated from the untransmitted parental chromosomes in the total data set.
probands used in the current study indicate that presence
of at least one copy of the “protective” haplotype delays
onset of the disease by ∼3 years (from 13.2 years to 16.5
years; ).Pp .03
The limited haplotypic diversity observed over the
BDNF locus indicates the presence of high-level linkage
disequilibrium (LD) among the transmitted chromo-
somes. The extent of marker-to-marker disequilibrium
is an important factor in interpreting marker-disease as-
sociation results. We therefore have genotyped six ad-
ditional markers (rs3763965, rs2352802, rs972096,
rs1387145, rs1464896, and rs2140887) (fig. 1a) in the
same families and have performed an extensive LD analy-
sis on the nontransmitted chromosomes to investigate
the extent of background LD in the BDNF gene and its
vicinity (157 kb upstream and 198 kb downstream of
the gene). The standard Lewontin D′ (Lewontin 1988)
and the square of the correlation coefficient (r2 or D2)
between adjacent markers was calculated from the pro-
gram UNPHASED, by use of the EM function for the
estimation of uncertain haplotype frequencies, via an
EM algorithm (table 4). Both measures range 0–1; how-
ever, for the r2 measure, unless the allele frequencies at
the two loci are identical, perfect correlation cannot be
achieved. Extremely strong LD was observed between
SNPs located within the BDNF gene, as also reported by
Sklar et al. (2002). In addition, extremely strong LD was
observed between SNPs from the BDNF gene and SNPs
located upstream of the BDNF gene, but not ones lo-
cated downstream (table 4). It should be noted that single-
locus analysis for the flanking SNPs did not show any
evidence for transmission distortion, with the exception
of rs972096 ( ), which is also the marker mostPp .0002
highly correlated (r2) to the core risk haplotype.
It has been suggested that a contribution of BDNF
to vulnerability to depression may be at the core of the
recently observed association with bipolar disorder (Li-
cinio and Wong 2002; Neves-Pereira et al. 2002). Most
of the work, to date, that supports such a role of BDNF
has been derived from studies that attempt to model de-
pression in animals (with perhaps most intriguing reports
that intracerebral administration of BDNF to animals
may have antidepressant properties) (Siuciak et al.
1997). However, despite the deficits in the 5-HT system,
heterozygous Bdnf/ mice were not more likely to dis-
play anxious or depressive-like behaviors (MacQueen et
al. 2001). The most frequently occurring comorbid ill-
nesses in patients with OCD are, by far, mood disorders
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and, in particular, DSM-IV MDD. Additional mood dis-
orders found in patients with OCD include dysthymia,
bipolar I, and bipolar II (Rasmussen and Eisen 1992;
Sobin et al. 1999). When patients with OCD are strat-
ified according to the presence or absence of comorbid
mood disorders, the statistical evidence weakens in ac-
cord with the decrease in the sample size, which excludes
comorbid mood disorders as the source of association
between BDNF and OCD (data not shown). Therefore,
this analysis fails to provide additional support for the
speculated BDNF/depression connection. It is, of course,
conceivable that partial disruptions in BDNF expression
or function may lead to perturbations in central neu-
rotransmission that, depending upon the presence of ad-
ditional genetic liability, can manifest as OCD, bipolar
disorder, MDD, or other related disorders. Alternatively,
BDNF-modulated traits or neuropsychological abnor-
malities other than depression may need to be explored
as a likely common basis for the observed association
of the BDNF gene with bipolar disorder and OCD.
The nature of protective variation in the BDNF locus
and the signaling pathways affected by it need to be
identified and explored as a candidate pharmacotherapy
target. In light of the extended background LD in this
locus, this may require functional studies in animal and
cellular models. The presence of strong LD upstream of
the BDNF gene does not allow exclusion of other genes
that map in that area. For example, the human homolog
of mouse Lin-7c is located only 667 bp from rs3763965
(fig. 1) and is an interesting candidate, on the basis of its
sequence homology to PSD-95, a gene involved in NMDA
receptor–synaptic localization and signaling. Neverthe-
less, the clustering of positively associated SNPs with vari-
able allele frequencies within the BDNF gene strongly
implicates this gene as the source of the association sig-
nal from this chromosomal region. Within the gene, the
Val66Met substitution seems to be a good candidate for
a causative variant, either by affecting the processing of
the mature form (thus modulating the growth-promot-
ing Trk pathway) or by affecting the interaction of the
secreted and the extracellularly processed pre-pro form
with p75 NTR, thus modulating apoptotic signaling
through this alternate pathway. Indeed, recent work,
which needs to be replicated, suggests that the Val/Met
polymorphism impacts intracellular trafficking and ac-
tivity-dependent secretion of BDNF (Egan et al. 2003).
Additional sequencing and functional studies need to
address whether other SNPs that affect the expression
(activity-dependent or constitutive) or splicing of the
BDNF gene may also be implicated.
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